Lipocine
LPCN
22 hedge funds and large institutions have $18.7M invested in Lipocine in 2014 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
29% more funds holding
Funds holding: 17 → 22 (+5)
21% less capital invested
Capital invested by funds: $23.7M → $18.7M (-$5.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$941K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$165K |
| 3 |
Millennium Management
New York
|
+$119K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$76.5K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$67.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$1.87M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$561K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$421K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$162K |
| 5 |
ISL
Ingalls & Snyder LLC
New York
|
-$20.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$338 | +4 | New |
|
LPCN Hedge Fund Activity: Q4 2014 in Review
22 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2014, worth a combined $18.7M — down 21% from $23.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LPCN positions and 4 closed out — a net gain of 6 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $941K. The largest seller was Janus Henderson Investors US, exiting entirely with an estimated $1.87M sold.
- 22 institutional investors held Lipocine (LPCN) as of Q4 2014, up from 17 in Q3 2014.
- Funds reported $18.7M of Lipocine stock for Q4 2014, down 21% quarter-over-quarter.
- 10 funds opened new Lipocine positions in Q4 2014 and 4 closed out, a net change of +6 holders.
- The largest Lipocine buyer in Q4 2014 was Royce & Associates, an estimated $941K added.
- The largest Lipocine seller in Q4 2014 was Janus Henderson Investors US, an estimated $1.87M sold.
Based on aggregated 13F filings for Q4 2014.